武田制药 TAK 深 沪
已收盘 08-21 16:00:00 美东时间
18.18
+0.050
+0.28%
华盛通- 最 高18.245
- 今 开18.09
- 成交量 147.91万股
- 最 低 18.08
- 昨 收 18.13
- 总市值 580.58亿
- 52周最高 18.895
- 市盈率 静 --
- 换手率 0.05%
- 52周最低 12.7276
- 委 比 -23.92%
- 总股本 31.94亿
- 历史最高 18.895
- 量 比 0.49
- 振 幅 0.91%
- 历史最低 8.5279
- 每 手 1
- 风险率 1.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多内部人交易｜武田制药披露一笔股票减持，金额约23.51万美元
美股上市公司武田制药（TAK）披露一笔内部人股票交易。文件显示，公司内部人Greenway (Nicola Deidre Petal)（Officer）202...
08-21 07:01
药物受理最新动态：Takeda Pharmaceutical Company Limited富马酸伏诺拉生片补充申请获受理
国家药品监督管理局药品审评中心数据显示，2026年8月14日，Takeda Pharmaceutical Company Limited的富马酸伏诺拉生片申请已...
08-14 18:15
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Royalty Pharma plc (NASDAQ:RPRX) on Wednesday entered into a $100 million funding agreement with Zealand Pharma in exchange for economic rights related to Zealand’s product, Rusfertide (PTG-300). This strategic move is expected to bolster Royalty Pharma’s portfolio and enhance its revenue streams. T...
08-14 01:07
Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’
Venture capitalist Vinod Khosla said artificial intelligence (AI) is rapidly expanding drug discovery, but traditional testing methods have failed to keep pace with the technology’s progress. AI and Human Tissue Drug Testing On Wednesday, in a post on X, Khosla said AI has produced what he described...
08-13 16:33
Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Takeda Pharmaceutical Co. Ltd.‘s (NYSE:TAK) Orzeyful (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. This oral orexin receptor 2 agonist marks the first treat...
08-06 23:16
Takeda Pharmaceutical Co Affirms FY2026 GAAP EPS Guidance of $0.66; Affirms FY2026 GAAP Sales Guidance of $29.585B
Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 GAAP EPS guidance from $0.66 to $0.66. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion.
07-30 15:47
Takeda Pharmaceutical reports Q1 results
Takeda Pharmaceutical press release (TAK): Q1 EPS: ¥154 vs ¥151 Y/Y (+1.5%; -11.8% CER). Revenue of ¥1.22T (-99.9% Y/Y) Operating profit: ¥358.9B vs ¥321.8B Y/Y (+11.5%; -0.5% CER). Q1 Operating margi...
07-30 14:53
Takeda Pharmaceutical Q1 Adj. EPS $0.48 Beats $0.39 Estimate, Sales $7.655B Beat $7.060B Estimate
Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.39 by 23.08 percent. This is a 7.69 percent decrease over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $7.655 billion...
07-30 14:50
美高层宣布两年后对仿制药征收100%关税！对创新药影响如何？港股通创新药ETF汇添富(159570)强势涨近3%！武田突破性1类新药在中国获批上市
今日，港股三大指数集体回调，港药逆市大涨。创新药含量100%的港股通创新药ETF汇添富（159570）放量大涨近3%，成交额迅速突破14亿元！截至昨日，最新规模...
07-22 10:19
